MET in ovarian cancer: Metastasis and resistance?

Por Tang, Chad, Jardim, Denis L, Hong, David
Publicado em 2014

Recent results of immunotherapy and perspectives for advanced NSCLC

Por Jardim, Denis L, de Melo Gagliato, Debora
Publicado no Lung Cancer Manag (2016)

Comprehensive characterization of malignant phyllodes tumor by whole genomic and proteomic analysis: biological implications for targeted therapy opportunities

Por Jardim, Denis L Fontes, Conley, Anthony, Subbiah, Vivek
Publicado em 2013

Noninvasive cancer biomarkers in solid malignancies: circulating tumor DNA—clinical utility, current limitations and future perspectives

Por de Melo Gagliato, Debora, Fontes Jardim, Denis L.
Publicado no Ann Transl Med (2018)

Lessons From the Development of the Immune Checkpoint Inhibitors in Oncology

Por Jardim, Denis L., de Melo Gagliato, Débora, Kurzrock, Razelle
Publicado no Integr Cancer Ther (2018)

The Challenges of Tumor Mutational Burden as an Immunotherapy Biomarker

Por Jardim, Denis L., Goodman, Aaron, Gagliato, Debora de Melo, Kurzrock, Razelle
Publicado no Cancer Cell (2020)

Analysis of Drug Development Paradigms for Immune Checkpoint inhibitors

Por Jardim, Denis L., de Melo Gagliato, Débora, Giles, Francis J., Kurzrock, Razelle
Publicado no Clin Cancer Res (2017)

MET alterations detected in blood-derived circulating tumor DNA correlate with bone metastases and poor prognosis

Por Ikeda, Sadakatsu, Schwaederle, Maria, Mohindra, Mandakini, Fontes Jardim, Denis L., Kurzrock, Razelle
Publicado no J Hematol Oncol (2018)

Efficacy and safety of anticancer drug combinations: a meta-analysis of randomized trials with a focus on immunotherapeutics and gene-targeted compounds

Por Jardim, Denis L., De Melo Gagliato, Débora, Nikanjam, Mina, Barkauskas, Donald A., Kurzrock, Razelle
Publicado no Oncoimmunology (2020)

Circulating Tumor DNA Detection in the Management of Anti-EGFR Therapy for Advanced Colorectal Cancer

Por Knebel, Franciele H., Bettoni, Fabiana, da Fonseca, Leonardo G., Camargo, Anamaria A., Sabbaga, Jorge, Jardim, Denis L.
Publicado no Front Oncol (2019)

Cyclin Pathway Genomic Alterations Across 190,247 Solid Tumors: Leveraging Large‐Scale Data to Inform Therapeutic Directions

Por Jardim, Denis L., Millis, Sherri Z., Ross, Jeffrey S., Woo, Michelle Sue‐Ann, Ali, Siraj M., Kurzrock, Razelle
Publicado no Oncologist (2020)

Landscape of Cyclin Pathway Genomic Alterations Across 5,356 Prostate Cancers: Implications for Targeted Therapeutics

Por Jardim, Denis L., Millis, Sherri Z., Ross, Jeffrey S., Woo, Michelle Sue‐Ann, Ali, Siraj M., Kurzrock, Razelle
Publicado no Oncologist (2021)

Phosphatidylinositol 3‐kinase pathway genomic alterations in 60,991 diverse solid tumors informs targeted therapy opportunities

Por Millis, Sherri Z., Jardim, Denis L., Albacker, Lee, Ross, Jeffrey S., Miller, Vincent A., Ali, Siraj M., Kurzrock, Razelle
Publicado no Cancer (2018)

Use of expansion cohorts in phase 1 trials and probability of success in phase 2 for 381 anticancer drugs

Por Bugano, Diogo D. G., Hess, Kenneth, Jardim, Denis L. F., Zer, Alona, Meric-Bernstam, Funda, Siu, Lillian L., Razak, Albiruni, Hong, David S.
Publicado no Clin Cancer Res (2017)

Impact of a Biomarker-Based Strategy on Oncology Drug Development: A Meta-Analysis of Clinical Trials Leading to FDA Approval

Por Fontes Jardim, Denis L., Schwaederle, Maria, Wei, Caimiao, Lee, J. Jack, Hong, David S., Eggermont, Alexander M., Schilsky, Richard L., Mendelsohn, John, Lazar, Vladimir, Kurzrock, Razelle
Publicado no J Natl Cancer Inst (2015)

FBXW7 Mutations in Patients with Advanced Cancers: Clinical and Molecular Characteristics and Outcomes with mTOR Inhibitors

Por Jardim, Denis L., Wheler, Jennifer J., Hess, Kenneth, Tsimberidou, Apostolia M., Zinner, Ralph, Janku, Filip, Subbiah, Vivek, Naing, Aung, Piha-Paul, Sarina A., Westin, Shannon N., Roy-Chowdhuri, Sinchita, Meric-Bernstam, Funda, Hong, David S.
Publicado em 2014

MET nucleotide variations and amplification in advanced ovarian cancer: characteristics and outcomes with c-Met inhibitors

Por Tang, Chad, Fontes Jardim, Denis L., Falchook, Gerald S., Hess, Kenneth, Fu, Siqing, Wheler, Jennifer J., Zinner, Ralph G., Naing, Aung, Tsimberidou, Apostolia M., De Melo Galgiato, Debora, Westin, Shannon N., Meric-Bernstam, Funda, Kurzrock, Razelle, Hong, David S.
Publicado no Oncoscience (2013)

SARS-CoV-2 testing for asymptomatic adult cancer patients before initiating systemic treatments: a systematic review

Por Haradaa, Guilherme, Antonacio, Fernanda F, Gongora, Aline BL, Behar, Marina H, Capareli, Fernanda C, Bastos, Diogo A, Munhoz, Rodrigo R, Costa, Frederico P, Jardim, Denis L, Arrais-Rodrigues, Celso, Novis, Yana, Katz, Artur, de Castro Junior, Gilberto
Publicado no Ecancermedicalscience (2020)

Analysis of MET Genetic Aberrations in Patients With Breast Cancer at MD Anderson Phase I Unit

Por de Melo Gagliato, Debora, Fontes Jardim, Denis L., Falchook, Gerald, Tang, Chad, Zinner, Ralph, Wheler, Jennifer J., Janku, Filip, Subbiah, Vivek, Piha-Paul, Sarina A., Fu, Siqing, Hess, Kenneth, Roy-Chowdhuri, Sinchita, Moulder, Stacy, Gonzalez-Angulo, Ana M., Meric-Bernstam, Funda, Hong, David S.
Publicado no Clin Breast Cancer (2014)

MET abnormalities in patients with genitourinary malignancies and outcomes with c-MET inhibitors

Por Jardim, Denis L. F., de Melo Gagliato, Débora, Falchook, Gerald, Zinner, Ralph, Wheler, Jennifer J., Janku, Filip, Subbiah, Vivek, Piha-Paul, Sarina A., Fu, Siqing, Tannir, Nizar, Corn, Paul, Tang, Chad, Hess, Kenneth, Roy-Chowdhuri, Sinchita, Kurzrock, Razelle, Meric-Bernstam, Funda, Hong, David S.
Publicado no Clin Genitourin Cancer (2014)